{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:26:01Z","timestamp":1782390361765,"version":"3.54.5"},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jpet.2026.104307","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:12:05Z","timestamp":1771546325000},"page":"104307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Positron emission tomography-based radiopharmaceuticals for imaging the expression and function of multidrug resistance P-glycoprotein"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7639-8874","authenticated-orcid":false,"given":"Deeksha","family":"Muralidhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jpet.2026.104307_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"issue":"10","key":"10.1016\/j.jpet.2026.104307_bib2","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3390\/pharmaceutics12100966","article-title":"Novel intrinsic mechanisms of active drug extrusion at the blood-brain barrier: potential targets for enhancing drug delivery to the brain?","volume":"12","author":"L\u00f6scher","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpet.2026.104307_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3389\/fphar.2016.00535","article-title":"The role of eukaryotic and prokaryotic ABC transporter family in failure of chemotherapy","volume":"7","author":"El-Awady","year":"2017","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.jpet.2026.104307_bib4","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0022-2275(20)31588-1","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"42","author":"Dean","year":"2001","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jpet.2026.104307_bib5","volume":"Vol 1141","year":"2019"},{"issue":"9","key":"10.1016\/j.jpet.2026.104307_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e30207","article-title":"Hypoxia modulates P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) drug transporters in brain endothelial cells of the developing human blood-brain barrier","volume":"10","author":"Mughis","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.jpet.2026.104307_bib7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"10.1016\/j.jpet.2026.104307_bib8","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1124\/dmd.118.081216","article-title":"Characterization of P-glycoprotein humanized mice generated by chromosome engineering technology: its utility for prediction of drug distribution to the brain in humans","volume":"46","author":"Yamasaki","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.jpet.2026.104307_bib9","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1208\/aapsj070101","article-title":"Characterization of the human MDR1 gene","volume":"7","author":"Bodor","year":"2005","journal-title":"AAPS J"},{"key":"10.1016\/j.jpet.2026.104307_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fonc.2020.00265","article-title":"Perplexing role of P-glycoprotein in tumor microenvironment","volume":"10","author":"Robinson","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.jpet.2026.104307_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09777","article-title":"P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease","volume":"8","author":"Ahmed Juvale","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.jpet.2026.104307_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.576559","article-title":"P-glycoprotein: one mechanism, many tasks and the consequences for pharmacotherapy of cancers","volume":"10","author":"Seelig","year":"2020","journal-title":"Front Oncol"},{"issue":"23","key":"10.1016\/j.jpet.2026.104307_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314667","article-title":"Regulation of P-glycoprotein in the brain","volume":"23","author":"Chai","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpet.2026.104307_bib14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-bioeng-071114-040723","article-title":"Positron emission tomography: current challenges and opportunities for technological advances in clinical and preclinical imaging systems","volume":"17","author":"Vaquero","year":"2015","journal-title":"Annu Rev Biomed Eng"},{"issue":"18","key":"10.1016\/j.jpet.2026.104307_bib15","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.3390\/molecules30183696","article-title":"Designing a small molecule for PET radiotracing: [18f]mc225 in human trials for early diagnosis in CNS pathologies","volume":"30","author":"Mastropasqua","year":"2025","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.jpet.2026.104307_bib16","first-page":"1571","article-title":"Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET","volume":"37","author":"Elsinga","year":"1996","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.jpet.2026.104307_bib17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s002280000253","article-title":"In vivo measurement of [11C]verapamil kinetics in human tissues","volume":"56","author":"Hendrikse","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104307_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ana.20369","article-title":"Blood-brain barrier dysfunction in parkinsonian midbrain in vivo","volume":"57","author":"Kortekaas","year":"2005","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.jpet.2026.104307_bib19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.clpt.2005.01.022","article-title":"Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography","volume":"77","author":"Sasongko","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.jpet.2026.104307_bib20","first-page":"1531","article-title":"Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function","volume":"47","author":"Ikoma","year":"2006","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.jpet.2026.104307_bib21","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/j.1528-1167.2007.01116.x","article-title":"Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil","volume":"48","author":"Langer","year":"2007","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.jpet.2026.104307_bib22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pscychresns.2010.05.002","article-title":"Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function","volume":"183","author":"de Klerk","year":"2010","journal-title":"Psychiatry Res"},{"issue":"suppl 6","key":"10.1016\/j.jpet.2026.104307_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1528-1167.2012.03704.x","article-title":"P-glycoprotein imaging in temporal lobe epilepsy: in vivo PET experiments with the Pgp substrate [11C]-verapamil","volume":"53","author":"Feldmann","year":"2012","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.jpet.2026.104307_bib24","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/jcbfm.2015.19","article-title":"Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study","volume":"35","author":"Bauer","year":"2015","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"10.1016\/j.jpet.2026.104307_bib25","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1021\/acs.molpharmaceut.0c01014","article-title":"Pharmacokinetic modeling of (R)-[11C]verapamil to measure the P-glycoprotein function in nonhuman primates","volume":"18","author":"Garc\u00eda-Varela","year":"2021","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.jpet.2026.104307_bib26","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.nucmedbio.2011.10.017","article-title":"Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil","volume":"39","author":"Verbeek","year":"2012","journal-title":"Nucl Med Biol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104307_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.nucmedbio.2011.06.009","article-title":"The influence of mass of [11C]-laniquidar and [11C]-N-desmethyl-loperamide on P-glycoprotein blockage at the blood-brain barrier","volume":"39","author":"Moerman","year":"2012","journal-title":"Nucl Med Biol"},{"issue":"7","key":"10.1016\/j.jpet.2026.104307_bib28","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12149-013-0725-5","article-title":"Imaging P-glycoprotein function in rats using [(11)C]-N-desmethyl-loperamide","volume":"27","author":"Farwell","year":"2013","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.jpet.2026.104307_bib29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejps.2016.06.005","article-title":"Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: a [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates","volume":"91","author":"Damont","year":"2016","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.jpet.2026.104307_bib30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/0271678X231202336","article-title":"[11C]metoclopramide is a sensitive radiotracer to measure moderate decreases in P-glycoprotein function at the blood-brain barrier","volume":"44","author":"Mairinger","year":"2024","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"10.1016\/j.jpet.2026.104307_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12987-024-00588-8","article-title":"[11C]metoclopramide PET can detect a seizure-induced up-regulation of cerebral P-glycoprotein in epilepsy patients","volume":"21","author":"Biali","year":"2024","journal-title":"Fluids Barriers CNS"},{"issue":"2","key":"10.1016\/j.jpet.2026.104307_bib32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2967\/jnumed.115.164350","article-title":"Imaging the impact of the P-glycoprotein (ABCB1) function on the brain kinetics of metoclopramide","volume":"57","author":"Pottier","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jpet.2026.104307_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7310146","article-title":"Positron emission tomography imaging reveals an importance of saturable liver uptake transport for the pharmacokinetics of metoclopramide","volume":"2018","author":"Caill\u00e9","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"issue":"7","key":"10.1016\/j.jpet.2026.104307_bib34","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2967\/jnumed.119.237198","article-title":"Imaging P-glycoprotein induction at the blood-brain barrier of a \u03b2-amyloidosis mouse model with 11C-metoclopramide PET","volume":"61","author":"Zoufal","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jpet.2026.104307_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106404","article-title":"Influence of P-glycoprotein on pulmonary disposition of the model substrate [11C]metoclopramide assessed by PET imaging in rats","volume":"183","author":"Mairinger","year":"2023","journal-title":"Eur J Pharm Sci"},{"issue":"12","key":"10.1016\/j.jpet.2026.104307_bib36","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.3390\/pharmaceutics14122650","article-title":"Impact of cytochrome induction or inhibition on the plasma and brain kinetics of [11C]metoclopramide, a PET probe for P-glycoprotein function at the blood-brain barrier","volume":"14","author":"Breuil","year":"2022","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.jpet.2026.104307_bib37","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1021\/mp5008103","article-title":"Synthesis and preclinical evaluation of three novel fluorine-18 labeled radiopharmaceuticals for P-glycoprotein PET imaging at the blood-brain barrier","volume":"12","author":"Savolainen","year":"2015","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.jpet.2026.104307_bib38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13550-020-00674-6","article-title":"Automated synthesis, preclinical toxicity, and radiation dosimetry of [18F]MC225 for clinical use: a tracer for measuring P-glycoprotein function at the blood-brain barrier","volume":"10","author":"Toyohara","year":"2020","journal-title":"EJNMMI Res"},{"issue":"13","key":"10.1016\/j.jpet.2026.104307_bib39","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1007\/s00259-021-05411-2","article-title":"Head-to-head comparison of (R)-[11C]verapamil and [18F]MC225 in non-human primates, tracers for measuring P-glycoprotein function","volume":"48","author":"Garc\u00eda-Varela","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.jpet.2026.104307_bib40","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1177\/0271678X16654493","article-title":"Evaluation of [18F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood-brain barrier in rats: kinetics, metabolism, and selectivity","volume":"37","author":"Savolainen","year":"2017","journal-title":"J Cereb Blood Flow Metab"},{"issue":"9","key":"10.1016\/j.jpet.2026.104307_bib41","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1021\/acs.molpharmaceut.0c00514","article-title":"Pharmacokinetic modeling of [18F]MC225 for quantification of the P-glycoprotein function at the blood-brain barrier in non-human primates with PET","volume":"17","author":"Garc\u00eda-Varela","year":"2020","journal-title":"Mol Pharm"},{"issue":"11","key":"10.1016\/j.jpet.2026.104307_bib42","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s12149-021-01666-9","article-title":"First clinical assessment of [18F]MC225, a novel fluorine-18 labelled PET tracer for measuring functional P-glycoprotein at the blood-brain barrier","volume":"35","author":"Toyohara","year":"2021","journal-title":"Ann Nucl Med"},{"issue":"13","key":"10.1016\/j.jpet.2026.104307_bib43","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1007\/s00259-023-06363-5","article-title":"Quantification of P-glycoprotein function at the human blood-brain barrier using [18F]MC225 and PET","volume":"50","author":"Mossel","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.jpet.2026.104307_bib44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11307-024-01975-1","article-title":"Oral administration of [18F]MC225 for quantification of P-glycoprotein function: a feasibility study","volume":"27","author":"Salvi de Souza","year":"2025","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"10.1016\/j.jpet.2026.104307_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70196","article-title":"Exploratory study of sex differences in P-glycoprotein function at the blood-brain barrier","volume":"18","author":"Salvi de Souza","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"12","key":"10.1016\/j.jpet.2026.104307_bib46","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1007\/s00259-025-07320-0","article-title":"Measurement of cyclosporin induced changes in P-glycoprotein function at the human blood-brain barrier using [18F]MC225 and PET","volume":"52","author":"Mossel","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.jpet.2026.104307_bib47","first-page":"493","article-title":"Evaluation of 11C-colchicine for PET imaging of multiple drug resistance","volume":"41","author":"Levchenko","year":"2000","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.jpet.2026.104307_bib48","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/sj.bjp.0706283","article-title":"New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics","volume":"145","author":"Bart","year":"2005","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.jpet.2026.104307_bib49","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.nucmedbio.2010.12.012","article-title":"Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography","volume":"38","author":"Yamasaki","year":"2011","journal-title":"Nucl Med Biol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104307_bib50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2191-219X-2-36","article-title":"[11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats","volume":"2","author":"Verbeek","year":"2012","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1016\/j.jpet.2026.104307_bib51","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.nucmedbio.2015.09.001","article-title":"(R)-[11C]emopamil as a novel tracer for imaging enhanced P-glycoprotein function","volume":"43","author":"Toyohara","year":"2016","journal-title":"Nucl Med Biol"},{"issue":"6","key":"10.1016\/j.jpet.2026.104307_bib52","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s11307-016-0965-6","article-title":"Synthesis and in vivo imaging of N-(3-[11C]methoxybenzyl)-2-(3-methoxyphenyl)ethylaniline as a potential targeting agent for P-glycoprotein","volume":"18","author":"Petroni","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.jpet.2026.104307_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105854","article-title":"Influence of ABC transporters on the excretion of ciprofloxacin assessed with PET imaging in mice","volume":"163","author":"Hern\u00e1ndez-Lozano","year":"2021","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.jpet.2026.104307_bib54","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11307-015-0883-z","article-title":"P-glycoprotein, not BCRP, limits the brain uptake of [(18)F]mefway in rodent brain","volume":"18","author":"Choi","year":"2016","journal-title":"Mol Imaging Biol"},{"issue":"11","key":"10.1016\/j.jpet.2026.104307_bib55","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.nucmedbio.2015.07.004","article-title":"PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a\/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier","volume":"42","author":"Vlaming","year":"2015","journal-title":"Nucl Med Biol"},{"issue":"9","key":"10.1016\/j.jpet.2026.104307_bib56","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1007\/s11095-012-0776-7","article-title":"Discrepancies in the P-glycoprotein-mediated transport of (18)F-MPPF: a pharmacokinetic study in mice and non-human primates","volume":"29","author":"Tournier","year":"2012","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.jpet.2026.104307_bib57","first-page":"1330","article-title":"Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates","volume":"44","author":"Kurdziel","year":"2003","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.jpet.2026.104307_bib58","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00259-011-1941-7","article-title":"A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer","volume":"39","author":"Wanek","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.jpet.2026.104307_bib59","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.nucmedbio.2013.05.005","article-title":"Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats","volume":"40","author":"M\u00fcllauer","year":"2013","journal-title":"Nucl Med Biol"},{"issue":"4","key":"10.1016\/j.jpet.2026.104307_bib60","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1124\/dmd.112.049148","article-title":"Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study","volume":"41","author":"Bankstahl","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.jpet.2026.104307_bib61","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.nucmedbio.2013.05.008","article-title":"[11C]quinidine and [11C]laniquidar PET imaging in a chronic rodent epilepsy model: impact of epilepsy and drug-responsiveness","volume":"40","author":"Syv\u00e4nen","year":"2013","journal-title":"Nucl Med Biol"},{"issue":"8","key":"10.1016\/j.jpet.2026.104307_bib62","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1007\/s00259-019-04589-w","article-title":"In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance","volume":"47","author":"Kannan","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.jpet.2026.104307_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22930-6","article-title":"Synthesis, characterization, and radiosynthesis of fluorine-18-AVT-011 as a Pgp chemoresistance imaging marker","volume":"12","author":"Kumar","year":"2022","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.jpet.2026.104307_bib64","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.nucmedbio.2012.08.005","article-title":"Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113","volume":"39","author":"Mairinger","year":"2012","journal-title":"Nucl Med Biol"},{"issue":"12","key":"10.1016\/j.jpet.2026.104307_bib65","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.2967\/jnumed.115.161273","article-title":"Breast cancer resistance protein and P-glycoprotein influence in vivo disposition of 11C-erlotinib","volume":"56","author":"Traxl","year":"2015","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.jpet.2026.104307_bib66","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/17425255.2013.741589","article-title":"Species differences in drug transporters and implications for translating preclinical findings to humans","volume":"9","author":"Chu","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jpet.2026.104307_bib67","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejps.2018.06.022","article-title":"Interspecies comparison of putative ligand binding sites of human, rat and mouse P-glycoprotein","volume":"122","author":"Jain","year":"2018","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"10.1016\/j.jpet.2026.104307_bib68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/jlcr.4019","article-title":"Strategies for designing novel positron emission tomography (PET) radiotracers to cross the blood-brain barrier","volume":"66","author":"Lindberg","year":"2023","journal-title":"J Labelled Comp Radiopharm"},{"issue":"8","key":"10.1016\/j.jpet.2026.104307_bib69","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.tips.2009.05.005","article-title":"PET radiotracers: crossing the blood-brain barrier and surviving metabolism","volume":"30","author":"Pike","year":"2009","journal-title":"Trends Pharmacol Sci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526005069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526005069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:15:55Z","timestamp":1777450555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526005069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0022356526005069"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104307","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positron emission tomography-based radiopharmaceuticals for imaging the expression and function of multidrug resistance P-glycoprotein","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104307"}}